If 7-OH Is "Synthetic," Where's the Patent? The Contradiction at the Heart of the Ban
NEWS ANALYSIS | July 5, 2026 | Kratom Truth Project
By Kratom Truth Project
Regulators have a word they keep using for 7-hydroxymitragynine: synthetic. HHS Secretary Kennedy called it a "dangerous synthetic opioid." The DEA's messaging leans on it. Trade groups repeat it. The word is doing enormous work in the campaign to schedule 7-OH.
There's just one problem. If 7-OH were actually synthetic, someone would own the patent on it. Nobody does. And the reason nobody does is the reason the entire "synthetic" framing collapses under thirty seconds of scrutiny.
You Cannot Patent Nature
Start with a fact that isn't in dispute anywhere: under U.S. patent law, you cannot patent a naturally occurring compound. This is settled law. A molecule that exists in nature, in a plant, produced by the plant's own biology, belongs to no one. It cannot be owned.
7-hydroxymitragynine occurs naturally in the Mitragyna speciosa plant. It forms through the plant's own metabolic processes. It is present in every batch of kratom leaf on earth. No chemist creates it. No laboratory is required to bring it into existence. It grows.
That is precisely why no company holds a patent on 7-OH itself. They can't. It's a product of nature, and products of nature are not patentable.
Now hold that fact next to the word regulators keep using. If 7-OH is "synthetic" — manufactured, lab-created, novel — then it would be patentable, and someone would have raced to patent it years ago. The pharmaceutical industry does not leave patentable opioid compounds lying around unclaimed. The absence of a 7-OH patent is not a minor detail. It is chemical and legal proof that 7-OH is exactly what its defenders say it is: a natural plant alkaloid.
You cannot have it both ways. A compound cannot be synthetic enough to schedule as a dangerous manufactured drug and natural enough that no one can patent it. Those two things are mutually exclusive. The industry wants both because both are useful — but reality only permits one.
What They're Actually Building in the Lab
Here is where the contradiction turns from sloppy into revealing.
While regulators call the natural plant compound "synthetic," pharmaceutical companies are, at this very moment, synthesizing actual laboratory-made analogs of kratom alkaloids and filing patents on them. These are genuinely synthetic. They are made by chemists. They do not occur in nature. And that is exactly what makes them patentable.
As we documented in The Patent Race, the public patent record is unambiguous. US Patent 9,757,382 B2 covers "Mitragynine Analogs" — synthetic derivatives with modified chemical structures. US Patent 10,370,356 B2 covers "Kratom Alkaloid Derivatives for Opioid Use Disorder." Patent application 20190144448 covers 7-hydroxymitragynine derivatives and pharmaceutical compositions. These are verifiable in the USPTO database. Clinical trials for synthetic mitragynine analogs are already registered on ClinicalTrials.gov and actively recruiting.
So follow the logic all the way through. The same regulatory apparatus that calls a natural, unpatentable plant alkaloid a "dangerous synthetic opioid" is clearing the market for genuinely synthetic, fully patentable opioid analogs made in a lab — the actual synthetic opioids in this story.
They are manufacturing the very thing they claim to be protecting the public from, while banning the natural version that no one can own.
The Word Is the Strategy
"Synthetic" is not a mistake. It is a chosen frame, and it serves two purposes at once.
Against the natural plant compound, "synthetic" is a scare word. It conjures fentanyl, lab-made poison, something alien and dangerous. It justifies scheduling. It frightens lawmakers and the public into supporting a ban on a compound that has never produced a single confirmed fatality in isolation.
For the pharmaceutical replacements, "synthetic" is a value proposition. The same industry that weaponizes the word against natural 7-OH will, when its patented analogs reach approval, market them as precisely engineered, pharmaceutical-grade, FDA-approved medicine. Synthetic becomes a selling point.
The word means "dangerous" when applied to the thing they want banned and "advanced" when applied to the thing they want to sell. That is not science. That is marketing wearing a lab coat.
KTP follows the money and the patents the mainstream press won't touch. Subscribe to KTP updates →
The Cannabis Precedent Already Proved This Works
None of this is speculative. It already happened, exactly once, with a different plant.
Natural cannabis was declared dangerous and prohibited. Then Marinol — synthetic THC, laboratory-made, fully patented — was approved and priced at six to eighteen times the cost of the natural plant. Then Epidiolex, pharmaceutical CBD, arrived at twenty to fifty times the cost of natural CBD. The natural version was the danger; the synthetic version was the medicine. The molecule was functionally the same. Only the ownership changed.
The kratom version of this playbook is running on schedule. Ban the natural, unpatentable compound. Approve the synthetic, patented analog. Charge a multiple of the price. Route the entire market through prescriptions, insurance, and pharmacy benefit managers. The "synthetic opioid" panic about natural 7-OH is not the obstacle to this plan. It is the mechanism of it.
The Test Any Honest Regulator Should Answer
There is a single question that cuts through the entire debate, and it can be posed to any official using the "synthetic" label:
If 7-OH is synthetic, produce the patent. Name the manufacturer. Show the synthesis. Explain who created this molecule that supposedly does not occur in nature.
They cannot, because it does occur in nature, in the plant, and has since long before any pharmaceutical company existed. The moment that question is asked honestly, the "synthetic opioid" framing is finished.
And if 7-OH is natural — which the patent law confirms, which the plant biology confirms, which the DEA's own acknowledgment that natural leaf below the threshold is exempt confirms — then the word "synthetic" needs to come out of every press release, every scheduling justification, and every lawmaker's talking points immediately.
They will not remove it, because the word is not describing chemistry. It is doing a job. And now you know what the job is.
The public comment period on HHS docket HHS-OASH-2026-0232 closes July 31, 2026. If you believe a natural plant compound should not be scheduled on the basis of a word that its own patent status proves false, the administrative record needs to hear it.
Submit Your Public Comment Before July 31
HHS Docket HHS-OASH-2026-0232 is open. KTP built a free generator that writes your personalized comment in under 2 minutes — no form letter, no account required.
Submit your comment:kratomtruthproject.org/comment-on-7-oh
Related KTP Coverage:
The Kratom Truth Project is an independent investigative journalism platform with no corporate funding or pharmaceutical industry affiliations. All claims are sourced from publicly available government documents, peer-reviewed research, patent filings, and regulatory records.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making decisions about your health or treatment.
Share This Investigation
